Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 10 12; 38(4):489-499.e3.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cohort Studies
Diarrhea
Humans
Ipilimumab
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Metastasis
Pneumonia
Prostatic Neoplasms, Castration-Resistant
Treatment Outcome

authors with profiles

Akash Patnaik